The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma
Open accessPublished version of a preprint
Abstract
PD-1 immune checkpoint inhibitors have produced encouraging results in patients with hepatocellular carcinoma (HCC). However, what determines resistance to anti–PD-1 therapies is unclear. We created a novel genetically engineered mouse model of HCC that enables interrogation of how different genetic alterations affect immune surveillance and response to immunotherapies. Expression of exogenous antigens in MYC;Trp53−/− HCCs led to T cell–mediated immune surveillance, which was accompanied by decreased tumor formation and increased survival. Some antigen-expressing MYC;Trp53−/− HCCs escaped the immune system by upregulating the β-catenin (CTNNB1) pathway. Accordingly, expression of exogenous antigens in MYC;CTNNB1 HCCs had no effect, demonstrating that β-catenin promoted immune escape, which involved defective recruitment of dendritic cells and consequently impaired T-cell activity. Expression of chemokine CCL5 in antigen-expressing MYC;CTNNB1 HCCs restored immune surveillance. Finally, β-catenin–driven tumors were resistant to anti–PD-1. In summary, β-catenin activation promotes immune escape and resistance to anti–PD-1 and could represent a novel biomarker for HCC patient exclusion. Significance: Determinants of response to anti–PD-1 immunotherapies in HCC are poorly understood. Using a novel mouse model of HCC, we show that β-catenin activation promotes immune evasion and resistance to anti–PD-1 therapy and could potentially represent a novel biomarker for HCC patient exclusion. See related commentary by Berraondo et al., p. 1003. This article is highlighted in the In This Issue feature, p. 983
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a mouse model of HCC, activation of WNT–β-catenin signalling promotes immune escape by impairing recruitment of dendritic cells and interfering with recognition by natural killer cells73.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [73]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Self-citationPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Flagged first, then by citations
Cited by
Sorted by citations
Items 801–900 of 928
Ning, Y.-M., Lin, K., Liu, X., Ding, Y., Jiang, X., Zhang, Z., Xuan, Y.-T., Dong, L., Liu, L., Wang, F., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20522694
Ning, Y., Lin, K., Liu, X., Ding, Y., Jiang, X., Zhang, Z., Xuan, Y.-T., Dong, L., Liu, L., Wang, F., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20522697
Hong, J. Y., Cho, H. J., Sa, J. K., Liu, X., Ha, S. Y., Lee, T., Kim, H., Kang, W., Sinn, D. H., Gwak, G.-Y., et al. (2022) · Figshare · doi:10.6084/m9.figshare.17913042
Hu, Y., Liu, J., Yu, J., Yang, F., Zhang, M., Liu, Y., Ma, S., Zhou, X., Wang, J., & Han, Y. (2022) · Figshare · doi:10.6084/m9.figshare.19219128
Tong, Q., Yi, M., Kong, P., Xu, L., Huang, W., Niu, Y., Gan, X., Zhan, H., Tian, R., & Yan, D. (2022) · Figshare · doi:10.6084/m9.figshare.21009597
Tong, Q., Yi, M., Kong, P., Xu, L., Huang, W., Niu, Y., Gan, X., Zhan, H., Tian, R., & Yan, D. (2022) · Figshare · doi:10.6084/m9.figshare.21009594
Zhang, N., Yang, X., Piao, M., Xun, Z., Wang, Y., Ning, C., Zhang, X., Zhang, L., Wang, Y., Wang, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26680693
Self-citationOversoe, S. K., Clement, M. S., Weber, B., Grønbæk, H., Hamilton-Dutoit, S. J., Sorensen, B. S., & Kelsen, J. (2021) · Figshare · doi:10.6084/m9.figshare.14385231
Ji, G., Yang, Q., Wang, S., Yan, X., Ou, Q., Gong, L., Zhao, J., Zhou, Y., Tian, F., Lei, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26700604
Self-citationHu, Y., Liu, J., Yu, J., Yang, F., Zhang, M., Liu, Y., Ma, S., Zhou, X., Wang, J., & Han, Y. (2022) · Figshare · doi:10.6084/m9.figshare.19219134
Hu, Y., Liu, J., Yu, J., Yang, F., Zhang, M., Liu, Y., Ma, S., Zhou, X., Wang, J., & Han, Y. (2022) · Figshare · doi:10.6084/m9.figshare.19219146
Xu, R.-C., Wang, F., Sun, J.-L., Abuduwaili, W., Zhang, G., Liu, Z.-Y., Liu, T., Dong, L., Shen, X.-Z., & Zhu, J.-M. (2024) · Figshare · doi:10.6084/m9.figshare.26552599
Hu, Y.-D., Wu, K., Liu, Y.-J., Zhang, Q., Shen, H., Ji, J., Fang, D., & Xi, S.-Y. (2023) · Figshare · doi:10.6084/m9.figshare.24499320
Tong, Q., Yi, M., Kong, P., Xu, L., Huang, W., Niu, Y., Gan, X., Zhan, H., Tian, R., & Yan, D. (2022) · Figshare · doi:10.6084/m9.figshare.21009606
Ji, G., Yang, Q., Wang, S., Yan, X., Ou, Q., Gong, L., Zhao, J., Zhou, Y., Tian, F., Lei, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26700622
Self-citationJi, G., Yang, Q., Wang, S., Yan, X., Ou, Q., Gong, L., Zhao, J., Zhou, Y., Tian, F., Lei, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25530372
Self-citationJi, G., Yang, Q., Wang, S., Yan, X., Ou, Q., Gong, L., Zhao, J., Zhou, Y., Tian, F., Lei, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25530234
Self-citationHu, Y., Liu, J., Yu, J., Yang, F., Zhang, M., Liu, Y., Ma, S., Zhou, X., Wang, J., & Han, Y. (2022) · Figshare · doi:10.6084/m9.figshare.19219152
Ji, G., Yang, Q., Wang, S., Yan, X., Ou, Q., Gong, L., Zhao, J., Zhou, Y., Tian, F., Lei, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26700610
Self-citationOrtiz-Barahona, V., Soler, M., Dávalos, V., García-Prieto, C. A., Janin, M., Setién, F., Fernández-Rebollo, I., Bech‐Serra, J. J., de la Torre, C., Guil, S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22814996
Self-citationNing, Y., Lin, K., Liu, X., Ding, Y., Jiang, X., Zhang, Z., Xuan, Y.-T., Dong, L., Liu, L., Wang, F., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20522685
Ning, Y.-M., Lin, K., Liu, X., Ding, Y., Jiang, X., Zhang, Z., Xuan, Y.-T., Dong, L., Liu, L., Wang, F., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20522688
Ortiz-Barahona, V., Soler, M., Dávalos, V., García-Prieto, C. A., Janin, M., Setién, F., Fernández-Rebollo, I., Bech‐Serra, J. J., de la Torre, C., Guil, S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22815002
Self-citationHu, Y., Liu, J., Yu, J., Yang, F., Zhang, M., Liu, Y., Ma, S., Zhou, X., Wang, J., & Han, Y. (2022) · Figshare · doi:10.6084/m9.figshare.19219143
Ji, G., Yang, Q., Wang, S., Yan, X., Ou, Q., Gong, L., Zhao, J., Zhou, Y., Tian, F., Lei, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26700607
Self-citationJi, G., Yang, Q., Wang, S., Yan, X., Ou, Q., Gong, L., Zhao, J., Zhou, Y., Tian, F., Lei, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26700601
Self-citationHong, J. Y., Cho, H. J., Sa, J. K., Liu, X., Ha, S. Y., Lee, T., Kim, H., Kang, W., Sinn, D. H., Gwak, G.-Y., et al. (2022) · Figshare · doi:10.6084/m9.figshare.17913048
Hong, J. Y., Cho, H. J., Sa, J. K., Liu, X., Ha, S. Y., Lee, T., Kim, H., Kang, W., Sinn, D. H., Gwak, G.-Y., et al. (2022) · Figshare · doi:10.6084/m9.figshare.17913054
Bao, R., Stapor, D., & Luke, J. J. (2020) · Figshare · doi:10.6084/m9.figshare.13147225
Ortiz-Barahona, V., Soler, M., Dávalos, V., García-Prieto, C. A., Janin, M., Setién, F., Fernández-Rebollo, I., Bech‐Serra, J. J., de la Torre, C., Guil, S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22814993
Self-citationOrtiz-Barahona, V., Soler, M., Dávalos, V., García-Prieto, C. A., Janin, M., Setién, F., Fernández-Rebollo, I., Bech‐Serra, J. J., de la Torre, C., Guil, S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22814999
Self-citationHu, Y., Liu, J., Yu, J., Yang, F., Zhang, M., Liu, Y., Ma, S., Zhou, X., Wang, J., & Han, Y. (2022) · Figshare · doi:10.6084/m9.figshare.19219140
Ji, G., Yang, Q., Wang, S., Yan, X., Ou, Q., Gong, L., Zhao, J., Zhou, Y., Tian, F., Lei, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26700616
Self-citationOrtiz-Barahona, V., Soler, M., Dávalos, V., García-Prieto, C. A., Janin, M., Setién, F., Fernández-Rebollo, I., Bech‐Serra, J. J., de la Torre, C., Guil, S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22814987
Self-citationNing, Y., Lin, K., Liu, X., Ding, Y., Jiang, X., Zhang, Z., Xuan, Y.-T., Dong, L., Liu, L., Wang, F., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20522682
Ortiz-Barahona, V., Soler, M., Dávalos, V., García-Prieto, C. A., Janin, M., Setién, F., Fernández-Rebollo, I., Bech‐Serra, J. J., de la Torre, C., Guil, S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22815005
Self-citationTong, Q., Yi, M., Kong, P., Xu, L., Huang, W., Niu, Y., Gan, X., Zhan, H., Tian, R., & Yan, D. (2022) · Figshare · doi:10.6084/m9.figshare.21009600
Ji, G., Yang, Q., Wang, S., Yan, X., Ou, Q., Gong, L., Zhao, J., Zhou, Y., Tian, F., Lei, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26700613
Self-citationPatient-Derived Models of Liver Cancer to Inform Clinical Treatment Paradigms: Recent Updates
Weinfurtner, K. M., Amin, R., Skuli, N., Gade, T. P. F., & Kaplan, D. E. (2026) · Seminars in Liver Disease · doi:10.1055/a-2779-4984
Bai, Y., & Yang, H. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-026-02043-4
Lin, S., Berdan, C. A., Sandy, M., Lu, X., Ramani, V., Nomura, D. K., Chen, X., Lee, J. V., & Goga, A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.28.702329
Sato, C., Taylor, M. T., & Martinez, D. (2023) · Asian journal of Current Research in Clinical Cancer · doi:10.51847/hldmpyjetk
Rodriguez, J. A., & Diaz, P. I. (2023) · Archive of International Journal of Cancer and Allied Science · doi:10.51847/elsecc2ogz
Immunotherapy in hepatocellular carcinoma: translating mechanistic insights into clinical advances
Khorasani, S. K., Boroumandi, S., Darzi, A., Shokouhfar, M., Abdali, P., Eini, P., Vanan, A. G., & Bahrami, N. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-026-02099-2 · Cited by 1
AXIN1 Mutated Hepatocellular Carcinoma
Torbenson, M. S., McCabe, C. E., Hohenstein, J. D., O’Brien, D., Chen, Z. E., Wu, T., Kakar, S., Tran, N. H., & Wang, C. (2026) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000002528
Trefoil Factor‐3 Is a Hypoxia‐Triggered Pro‐Tumorigenic Factor in Hepatoblastoma
Martínez-Pérez, L. A., Latasa, M., Uriarte, I., López-Pascual, A., Elurbide, J., Strnad, P., Fraňková, S., Sticová, E., Fabián, O., Arechederra, M., et al. (2026) · Liver international (Print) · doi:10.1111/liv.70592
Meng, Y., Jing, L., Chen, Y. K., Zhan, S., Xiong, F., & Chen, W. (2026) · Open Research (University of Surrey) · doi:10.1002/viw.20250078
Li, B., Wei, P., Xie, B., Zhong, X., Wang, X., Lou, X., Zhang, T., & Dong, C. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218464 · Cited by 1
Rôle de la voie de signalisation Hippo dans le développement des ostéosarcomes
Morice, S. (2019) · theses.fr (ABES) · doi:10.70675/32829b80z5982z4f52z949bz98b3ed38b7c0
Mécanismes d'immunosurveillance NKG2D et DNAM-1 dans le carcinome hépatocellulaire
Cadoux, M. (2019) · theses.fr (ABES) · doi:10.70675/a6660468zb747z4a0czb963z900d06687ec7
Hobeika, C. (2022) · theses.fr (ABES) · doi:10.70675/4c247323z584fz42b6za12cze7812b01da9e
Coopération oncogénique et effets métaboliques de FGF19 dans le carcinome hépatocellulaire
Bedoya, J. U. (2021) · theses.fr (ABES) · doi:10.70675/d2df913bz04e7z457dzb21dzf6ae23303e0c
Rôle de LECT2 dans les maladies stéatosiques non alcooliques du foie
Pham, S. (2020) · theses.fr (ABES) · doi:10.70675/3693bfe6z9d91z4045za9a9zc37497dc9c1b
Rôle de l'isoforme A du récepteur de l'insuline dans l'homéostasie et la carcinogenèse hépatiques
Léandre, F. (2024) · theses.fr (ABES) · doi:10.70675/df1bc445z5d98z462dzbc59za0d4015bcf04
Fascin-1 as a druggable target in Hepatoblastoma
Dif, L. (2024) · theses.fr (ABES) · doi:10.70675/397187b4z98e4z4886zb816z1a59af68ea71
DiffDriver Detects Context-Associated Selection of Cancer Driver GenesPreprint
Zhou, J., Zhang, Q., Song, L., He, X., & Zhao, S. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.06.716771
Sheng, X., & Qin, J.-M. (2026) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v34.i3.190
Targeted Therapy and Immunotherapies in Hepatocellular Carcinoma: Mechanisms and Clinical Studies
He, P. C., Xie, S., Xie, K., Gao, F., Cai, Y., Huang, Y., Liu, C., Wu, H., Lyu, Y., & Lan, T. (2026) · MedComm · doi:10.1002/mco2.70694
The role of YY1 in promoting cancer immune evasion
Li, M., Zhang, J., Fan, R., Liu, M., Li, D., & Sui, G. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189595
Tumor cell intrinsic mechanisms of immune escape
Sriram, G., Aquib, A., Glassman, R., & Birge, R. B. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02891-3
Liu, L., Tang, B., Ma, F., Wang, H., Chen, B., Zhang, N., Liu, X., Lyu, Y., & Dong, D. (2026) · International Journal of Clinical Practice · doi:10.1155/ijcp/6800480
Scalera, S., Cipriani, L., Scarinci, A., Schiavoni, G., Fanciulli, M., Ciuffreda, L., Nicola, F. D., Goeman, F., Pescarmona, E. O., Diodoro, M. G., et al. (2026) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2026.105049
Zhou, Y., Chen, P., Wang, Z., Gui, L., Zheng, Z., Gao, W., & Ma, B. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012347
Next-Generation Sequencing in Hepatobiliary Carcinomas
Sioletic, S., & Baiocchini, A. (2026) · Current clinical pathology · doi:10.1007/978-3-032-18790-1_5
He, T., Zhang, L., & Zhao, Q. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2025.74
ATF4 programs proline-dependent immune evasion in β-Catenin-driven hepatocellular carcinomaPreprint
Infante, S., María, E. S., Finnemore, A., Barace, S., Martinez-Montes, A., Damone, F., Arcelus, S., García-Porrero, G., Hosseini, N., Miraval, E., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.12.724215
Targeting tumor-intrinsic STK40 induces immune vulnerability and drives T cell reinvigoration
Zhu, L., Zhang, S., Li, B., Liu, X., Yang, C. C.-K., Tang, X. Y., Chai, J., Yang, X., Yu, C., Liao, H., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.05.001
Zhang, Q., Kong, Y., Long, Y., Li, X., Wang, L., Luo, Z., Yang, X., Xie, Y., Yu, Q., Yu, J., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102837
Ye, Y., Xu, Z., Wang, J. X., Chen, C., Peng, Y., & Li, B. (2026) · Human Mutation · doi:10.1155/humu/6223429
Jia, Z., Liu, M., Dou, J., Lan, Y., Xie, Y., Li, J., Huang, J., Bian, Z., & Zheng, J. (2026) · Discover Oncology · doi:10.1007/s12672-026-05222-7
Tang, S., Cai, H., Wu, Z. Z., Huang, S., Zhao, L., Wu, L., Gong, L., & Guo, W. (2026) · BMC Cancer · doi:10.1186/s12885-026-16286-7
New insights into immunotherapy for hepatocellular carcinoma
Li, S., He, H., Wen, W., & Wang, H. (2026) · Scientia Sinica Vitae · doi:10.1360/ssv-2026-0107
Fang, X., Cai, Y., Li, Z., Peng, X., Yang, S., Zhao, Z., & Li, Y. (2026) · Discover Oncology · doi:10.1007/s12672-026-05331-3
Väyrynen, V., Eloranta, K., Talka, M., Tuhkala, A., Lohi, J., Varjosalo, M. T., Kyrönlahti, A., Jalkanen, S., Hollmén, M., Pihlajoki, M., et al. (2026) · American Journal Of Pathology · doi:10.1016/j.ajpath.2026.05.006
Crosstalk between circRNAs and the classic signaling pathways in IBD
Jie, M.-M., Liao, Q., & Liu, C. (2026) · RNA Biology · doi:10.1080/15476286.2026.2684781
Figueiredo, C. R., & Park, G. (2026) · Pharmaceutical science. · doi:10.5772/intechopen.1015805
Lee, J., Lee, H. W., Park, M. R., Shin, S., Choi, J. R., Park, H. J., Cho, K. J., Lee, S., & Park, J. Y. (2026) · Liver Cancer · doi:10.1159/000553049
Orthotopic murine model of hepatocellular carcinoma
Silva, L., Repáraz, D., & Ruiz, M. (2026) · Methods in cell biology · doi:10.1016/bs.mcb.2026.06.003
A Paracrine Dietary Lipid Axis Constrains Antitumor Immunity in Liver CancerPreprint
Ciobu, N., Kumari, R., Kumar, J. S., Balaseviciute, U., Iftesum, M., Mitchell, J., Ruiz, J., Flowers, S., Nishikawa, K., Cano-Segarra, G., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.25.734592
Self-citationZhu, N., Zhang, G. Z., Shen, X., Chen, Z., Li, Y., Chen, D., & Jia, H. (2026) · Biology Direct · doi:10.1186/s13062-026-00873-6
He, H., 乔志恒, Gai, X., Ji, G., & Liu, S. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105457
TERT drives liver tumorigenesis beyond telomere elongation
Braud, L., Vernerey, J., Guillé, A., Cordier, P., Ginet, C., Egger, T., Bernabe, M., Churikov, D., Costa, Q. D., Meghraoui, A., et al. (2026) · Life Science Alliance · doi:10.26508/lsa.202603660
Yuza, K., & Pawlik, T. M. (2026) · Cancers · doi:10.3390/cancers18142234
Chen, S., Yan, L., Zeng, J., Chen, Y., Zhao, X., Meng, W., Zhuang, J., Chen, F., Guo, Y., El‐Aty, A. M. A., et al. (2026) · Food Frontiers · doi:10.1002/fft2.70319
Xu, J., Yang, L., Wang, S., 吴柳生, Liang, Y., Xie, X., Wang, W., Gao, L., Sun, K., & Yan, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1870326
Self-citationPreclinical efficacy and safety of Tegavivint in Wnt-activated hepatocellular carcinomaPreprint
Suzuki, T., Curran, C., Drake, T. M., May, S., Swe, K. L. Y., Γεωργακοπούλου, Α., Quince, M., Chalmers, F. E., Paterson, E., Duncan, A. D., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.14.738585
Cai, M., Liao, Y., Lin, J., Chen, X., Wang, J., Li, Z., Yang, Z., & Cai, D. (2026) · Clinical and Translational Discovery · doi:10.1002/ctd2.70178
Ham, E., Boedeker, K., Keating, C. R., Ye, R.-S., Montalbano, F., Mankaruse, S., Ding, X., Rennhack, J. P., & Qiu, W. (2026) · Molecular Carcinogenesis · doi:10.1002/mc.70156
Immunotherapy Rechallenge in HCC : A Second Chance for Response?
da Fonseca, L. G., Guerrero, A. J. G., & Muñoz, S. (2026) · Liver International · doi:10.1111/liv.70832
Metabolic Dysfunction–Associated Steatotic Liver Disease Reprograms the Hepatic Metastatic Niche
Karabicici, M., & Seki, E. (2026) · Seminars in Liver Disease · doi:10.1055/a-2921-0092
Jones, E., Eppler, N., Ahamed, F., & Zhang, Y. (2026) · Livers · doi:10.3390/livers6040074 · Cited by 2
Fu, C., Fang, Z., Zhang, Y., & Xu, W. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1918635
Sharma, A., Tan, J. K., Sisodia, R., Kumar, H., Bharadwaj, H. R., Sonaiya, S., Shah, Y., Ali, H., Dhali, A., Abdul, R. H. M., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1894185
Yuza, K., Kawashima, J., Akabane, M., & Pawlik, T. M. (2026) · Cancers · doi:10.3390/cancers18162696
Tian, T., Xue, Y., Sun, C., Yang, L., Wang, J., Jin-Smith, B., Barkin, J., Nzegwu, M., Jia, L., Zhou, H., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-77089-9
Metadata
- Authors
- Ruiz de Galarreta, M., Bresnahan, E., Molina-Sánchez, P., Lindblad, K. E., Maier, B., Sia, D., Puigvehi, M., Miguela, V., Casanova-Acebes, M., Dhainaut, M., Villacorta-Martin, C., Singhi, A. D., Moghe, A., von Felden, J., Tal Grinspan, L., Wang, S., Kamphorst, A. O., Monga, S. P., Brown, B. D., Villanueva, A., Llovet, J. M., Merad, M., & Lujambio, A.
- Affiliations
- 1Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
- Tisch Cancer Institute (US)
- Icahn School of Medicine at Mount Sinai (US)
- 2Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
- University of Pittsburgh (US)
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Corresponding author
- Lujambio, Amaia
- ORCID
- Ruiz de Galarreta, Marina
- Molina-Sánchez, Pedro
- Lindblad, Katherine E.
- Maier, Barbara
- Sia, Daniela
- Puigvehi, Marc
- Miguela, Verónica
- Casanova-Acebes, María
- Dhainaut, Maxime
- Singhi, Aatur D.
- Moghe, Akshata
- von Felden, Johann
- Wang, Shuang
- Kamphorst, Alice O.
- Monga, Satdarshan P.
- Brown, Brian D.
- Villanueva, Augusto
- Llovet, Josep M.
- Lujambio, Amaia
- Venue
- Cancer Discovery
- Published
- 2019-08-01
- Volume
- 9
- Issue
- 8
- Pages
- 1124-1141
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC6677618
- OpenAlex
- W2952311394
- Cited by
- 912
- References
- 67
- Citations by year
- 2026: 114 · 2025: 121 · 2024: 158 · 2023: 169 · 2022: 156 · 2021: 116 · 2020: 67 · 2019: 11
- FWCI
- 36.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Cancer Discovery (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Damon Runyon Cancer Research FoundationDamon Runyon Cancer Research Foundation (Damon Runyon) (DR52-18)
- HHS | NIH | National Cancer InstituteHHS | NIH | National Cancer Institute (NCI) (R37CA230636, P30 CA196521)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- β-catenin signaling, hepatocellular carcinoma, immune evasion, anti-PD-1 resistance, PD-1 inhibitors, tumor surveillance, c-Myc, Trp53, dendritic cell recruitment, T cell function, RANTES, chemokines, genetically engineered mouse models, immunotherapy biomarkers
- MeSH terms
- Antineoplastic Agents, Immunological, Animals, Dendritic Cells, Disease Models, Animal, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Oncogenes, Biomarkers, Tumor, Signal Transduction, Gene Expression, Treatment Outcome, CD8-Positive T-Lymphocytes, Drug Resistance, Neoplasm, Tumor Escape, Xenograft Model Antitumor Assays, Cell Line, Tumor, beta Catenin, Mice, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
